The development of antidepressants: Experience and prospects;Développement des antidépresseurs: Acquis et perspectives

Presse Medicale

Volumn 32, Issue 11, 2003, Pages 519-522

  Bouvier, Nicolas ^a   Trenque, T ^a   Millart, H ^a  

^a HÔPITAL MAISON BLANCHE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE; GESTAGEN; NEUROPEPTIDE Y; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; NORADRENALIN; PROTIRELIN; SEROTONIN; SUBSTANCE P;

DEPRESSION; DRUG RESEARCH; HISTORY OF MEDICINE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PATHOPHYSIOLOGY; REVIEW; SYNAPTIC TRANSMISSION;

ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER; FORECASTING; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, NEUROTRANSMITTER; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 0344405686     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Schildkraut J.-J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-522
2. Banarjee SP. Development of β adrenergic receptor subsentivity by antidepressants. Nature 1977; 268: 455-6
3. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51: 248-51
4. Stahl SM. Essential psychopharmacology. Neuroscientific basis and practical applications. Cambridge University Press 2000.
5. Kapur S, Mann J.-J. Role of the dopaminergic system in depression. Biol Psychiatry 1992; 32: 1-17
6. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 1996; 739: 70-8
7. Baby S, Nguyen M, Tran D, Raffa RB. Substance P antagonists: the next breakthrough in treating depression? J Clin Pharm Ther 1999; 24: 461-9
8. Widerlov E, Lindstrom LH, Wahlestedt C, Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 1988; 22: 69-79
9. Heilig M, Wahlestedt C, Ekman R, Widerlov E. Antidepressants drugs increase the concentration of neuropeptide Y [NPY]-like immunoreactivity in the rat brain. Eur J Pharmacol 1988; 147: 465-7
10. Stogner KA, Holmes PV. Neuropeptide Y exerts antidepressant-like effects in the forced swim test in rats. Eur J Pharmacol 2000; 387: R9-R10
11. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression. J Endocrinol 1999; 160: 1-12
12. Romeo E, Strohle A, Spalletta G et al. Effects of antidepressants treatments on neuroactive steroids in major depression. Am J Psychiatry 1998; 155: 910-13
13. Pepin MC, Govindan MY, Barden N. Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol Pharmacol 1992; 41: 1016-22
14. Sattin A. The role of TRH and related peptides in the mechanism of action of ECT. J ECT 1999; 15: 76-92.
15. De Wied D, Van Ree J.-M. Neuropeptides: animal behaviour and human psychopathology. Eur Arch Psychiatry Neurol Sci 1989; 238: 323-331